Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Current Deferred Revenue (2022 - 2025)

Bioregenx's Current Deferred Revenue history spans 4 years, with the latest figure at $60227.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $60227.0 for Q4 2025, down 69.43% from a year ago — trailing twelve months through Dec 2025 was $60227.0 (down 69.43% YoY), and the annual figure for FY2025 was $60227.0, down 69.43%.
  • Current Deferred Revenue for Q4 2025 was $60227.0 at Bioregenx, down from $95775.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $629000.0 in Q4 2022 to a low of $60227.0 in Q4 2025.
  • The 4-year median for Current Deferred Revenue is $192610.0 (2024), against an average of $234690.9.
  • Peak annual rise in Current Deferred Revenue hit 36.12% in 2025, while the deepest fall reached 69.43% in 2025.
  • Year by year, Current Deferred Revenue stood at $629000.0 in 2022, then crashed by 43.72% to $354000.0 in 2023, then crashed by 44.35% to $197000.0 in 2024, then tumbled by 69.43% to $60227.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $60227.0, $95775.0, and $125174.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.